Literature DB >> 2587023

A comparative study concerning the treatment of active toxoplasmic retinochoroiditis with argon laser and medication (follow-up 2-9 years).

G P Theodossiadis1, C Koutsandrea, A Tzonou.   

Abstract

Thirty-three eyes (i.e. 33 patients) with active toxoplasmic retinochoroiditis were treated and followed up for a 2 to 9 year period. The patients were divided into two groups. The first was treated with laser, while the second received medication. The division into two groups was made in order to discover possible differences between the two groups concerning success rate, time of regression of the lesion recurrences and complications. The study showed the following results: there was no difference as to the rate of overall success between the two groups. The laser produced no result in the cases where the active retinochoroidal lesion was larger than 2 disc diameters. The regression of the active lesion in the laser group was accomplished in 25-50 days, while in the medication group took 50-150 days. Recurrences after treatment were found in both groups. However, the starting point of recurrences differed in each group.

Entities:  

Mesh:

Year:  1989        PMID: 2587023     DOI: 10.1159/000310020

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  3 in total

1.  Retinal vascular involvement in acute toxoplasmic retinochoroiditis.

Authors:  P Theodossiadis; S Kokolakis; I Ladas; A C Kollia; D Chatzoulis; G Theodossiadis
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

Review 2.  Antibiotics versus no treatment for toxoplasma retinochoroiditis.

Authors:  Eli Pradhan; Sanjeeb Bhandari; Ruth E Gilbert; Miles Stanford
Journal:  Cochrane Database Syst Rev       Date:  2016-05-20

Review 3.  Current treatment of toxoplasma retinochoroiditis: an evidence-based review.

Authors:  Meredith Harrell; Petros E Carvounis
Journal:  J Ophthalmol       Date:  2014-08-13       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.